of t cells engineered to express artificial chimeric antigen (ag) receptors (cars) targeting tumor cell surface-specific ag is an exciting new approach for cancer immunotherapy.clinical trials in patients with advanced b-all treated with car-t cells against cd19 have shown impressive disease remission; However relapse still occurs with loss of cd19.
The researchers found that adoptive transfer
of these mutant-protein-specific tumor-infiltrating lymphocytes with interleukin-2 and checkpoint blockade mediated a reduction in cancer, with the target tumor burden reduced by 51 percent at the first evaluable time points six weeks after cell transfer.
Herein, we describe the key role played by NK cells in the setting of haploidentical (haplo) HSCT as protection against leukemia recurrence, review the adoptive transfer
of NK cells for leukemia immunotherapy with or without HSCT, and enumerate the novel approaches being investigated to enhance NK activity.
In the adoptive transfer
of pDCs, mice were immunized and treated with CpG-A or vehicle as described above.
Studies conducted by the National Cancer Institute of adoptive transfer
of in vitro-selected tumor-infiltrating lymphocytes were the first to demonstrate the potential of T-cell immunotherapy to eradicate solid tumors.
. To induce T1D by adoptive transfer
, purified [CD4.sup.+] diabetogenic T cells from prediabetic NOD mice were injected i.v.
We used C57BL/6 (B6, [CD90.2.sup.+][CD45.2.sup.+]) mice for all time-course studies and examination of [CD4.sup.+] T-cell subsets; [AhR.sup.-/-] ([B6.AhR.sup.tm1Bra]) mice crossed with C57BL/6 mice ([AhR.sup.+/+]) for experiments to determine whether offspring need to express AhR in order to experience changes due to TCDD exposure during development; and C57BL/6 (B6, [CD90.2.sup.+][CD45.2.sup.+]), B6-LY5.2/Cr ([CD90.2.sup.+][CD45.1.sup.+]), and [B6.PL-Thy1.sup.a]/CyJ ([CD90.1.sup.+][CD45.2.sup.+]) mice for adoptive transfer
Within these cell populations, they then identified subgroups and proceeded with a series of single-cell adoptive transfer
experiments, in which the aftermath of immune responses could be analyzed in detail.
These results provide important insight into continued efforts to develop combined chemoimmunotherapy modalities for patients with brain lymphomas, which could include systemic adoptive transfer
of tumor-specific T cells and DNA vaccination as well as local cytokine and chemotherapy delivery [11,17, 25-27].
. Splenocytes were isolated from 12-week-old female NOD mice.
of Tregs has shown benefits in Ang II-models of hypertension.
Activating the immune system for therapeutic benefits has long been a strategic goal for immunologists and oncologists." He pointed out that different specific-immunotherapeutic modalities, including cancer vaccines and adoptive transfer
had been developed and examined in different phases of clinical trials.